New drug MTX-101 enters first human tests for type 1 diabetes
NCT ID NCT06324604
First seen Mar 28, 2026 · Last updated Jun 18, 2026 · Updated 12 times
Summary
This early-stage study tests a new drug called MTX-101 in healthy adults and people with type 1 diabetes. The main goal is to check for side effects, see how long the drug stays in the body, and learn how it affects immune cells. About 96 participants will receive either a single dose or multiple doses of the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Austin Health
RECRUITINGHeidelberg, Victoria, 3084, Australia
Contact
-
St Vincent's Hospital Melbourne (SVHM)
RECRUITINGFitzroy, 3065, Australia
Contact
-
The Royal Melbourne Hospital
RECRUITINGMelbourne, Victoria, 3050, Australia
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.